Answer
The most common adverse reactions of any grade to tivozanib in patients with advanced renal cell carcinoma include hypertension (47.6%), dysphonia (26.9%), fatigue (25.8%) and diarrhoea (25.5%).
Sources for this answer
- Fotivda 890mcg hard capsulesRecordati UK Ltd · emc · SmPC §4.8 Undesirable effects · Version 13Document updated
Sources checked